LXRX News

Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026

Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy

Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease

Chronic Pain Associated with Painful Diabetic Neuropathy (PDN) - 7MM Market Insights, Epidemiology, and Forecast - 2036 | Non-Opioid Innovation Expands 7MM Growth Opportunities

LX-9211 Market Outlook 2026-2034 | Sales Forecast Highlights Emerging Commercial Opportunities

Lexar and Leica Present Threads of Time: A Journey Through Silk and Lens at Leica Gallery Amsterdam

Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences

Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

Form 8-K